Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027Data from the ongoing parallel BROADEN2 Phase 2b atopic ...

Kymera Therapeutics KYMR announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to ...

Dr. Douglas Lotz steps in as Interim CEO, with a clear focus on patient-first care. Building on a legacy of trusted ...

Rezpegaldesleukin may be an effective therapeutic option for adults with moderate to severe AD as well as those with comorbid ...

New Study Suggests We’ve Been Targeting the Wrong Asthma Trigger *For decades, asthma treatment has focused on molecules called leukotrienes. These compounds cause inflammation, tighten airways, and ...

New research reveals hidden inflammation chemicals in asthma that rise with symptom severity and may allow earlier, simpler ...

Approximately one-third of asthma patients may actually not have the long-term inflammatory disease, according to new research published in JAMA. For the study, researchers recruited 701 participants ...

A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...

In this video, Shikha Saxena, MD, attending physician of the division of pulmonary and sleep medicine at the Children's ...

Researchers and doctors are beginning to modernize asthma treatment using innovative therapies. Asthma is a common, chronic and treatable lung disease that touches nearly every family in America. It ...

An asthma intervention helps patients, but may hurt hospitals. April 13, 2010— -- By taking steps outside the confines of their own facilities, more and more hospitals have been able to keep ...

Mounting evidence points to a link between new-onset allergies and Long COVID, with mast cell activation syndrome as a ...